The Italian Journal of Neurological Sciences

, Volume 14, Issue 2, pp 129–137 | Cite as

Antiphospholipid antibodies syndrome and cerebral ischemia

  • Severi S. 
  • Ghezzi M. 
  • Felici M. 
  • Miele A. 
Original Articles

Abstract

Antiphospholipid antibodies are acquired circulating immunoglobulins that interact with phospholipids. These factors may manifest anticoagulant properties in vitro, interfering with phospholipid-dependent coagulation tests. They are not, however, associated with a hemorrhagic diathesis. Indeed, far from exerting the anticoagulant properties they possess in vitro, they are associated with episodes of thromboembolism, systemic and cerebral. We report the clinical and instrumental findings in 7 patients with ischemic stroke and circulating antiphospholipid antibodies classifiable as antiphospholipid antibodies syndrome.

Key Words

Anticoagulants antiphospholipid antibodies 

Sommario

Gli anticorpi antifosfolipidi sono immunoglobuline circolanti acquisite che interagiscono con i fosfolipidi. Questi fattori, in vitro, possono manifestare proprietà anticoagulanti interferendo con i test della coagulazione fosfolipidi-dipendenti. Tali anticorpi non sono tuttavia associati a diatesi emorragica. Infatti, contrariamente alle loro proprietà anticoagulanti in vitro, essi sono correlati ad episodi tromboembolici sistemici e cerebrali.

Vengono descritti i reperti clinici e strumentali osservati in sette pazienti con ictus ischemico ed anticorpi antifosfolipidi in circolo, inquadrabili nella sindrome da anticorpi antifosfolipidi.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Asherson R.A.:A “primary” antiphospholipid syndrome? J. Rheumatol. 15:1742–1746, 1988.PubMedGoogle Scholar
  2. [2]
    Asherson R.A., Khamashta M.A., Gil A.G. et al.:Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am. J. Med. 86:391–399, 1989.CrossRefPubMedGoogle Scholar
  3. [3]
    Asherson R.A., Mercey D., Phillips G. et al.:Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann. Rheum. Dis. 46:605–611, 1987.PubMedGoogle Scholar
  4. [4]
    Bernard C., de Moerloose P.:Anticorps anticardiolipine et thromboses. Med. et Hyg. 48:166–169, 1990.Google Scholar
  5. [5]
    Blatt P.M., Martin S.E.:The lupus anticoagulant. Arch. Pathol. Lab. Med. 111:113–114, 1987.PubMedGoogle Scholar
  6. [6]
    Bloom E.J., Abrams D.I., Rodgers G.:Lupus anticoagulant in the acquired immunodeficiency syndrome. J.A.M.A. 256:491–493, 1986.PubMedGoogle Scholar
  7. [7]
    Brey R.L., Hart R.G., Sherman D.G., Tegeler C.H.:Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 40:1190–1196, 1990.PubMedGoogle Scholar
  8. [8]
    Briley D.P., Coull B.M., Goodnight S.H. Jr.:Neurological diseases associated with antiphospholipid antibodies. Ann. Neurol. 25:221–227, 1989.CrossRefPubMedGoogle Scholar
  9. [9]
    Couley C.L., Hartmann R.C.:A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J. Clin. Invest. 31:621–622, 1952.Google Scholar
  10. [10]
    Coull B.M., Bourdette D.N., Goodnight S.H. et al.:Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke 18:1107–1112, 1987.PubMedGoogle Scholar
  11. [11]
    Coull B.M., Goodnight S.H.:Antiphospholipid antibodies, prethrombotic states, and stroke. Stroke 21:1370–1374, 1990.PubMedGoogle Scholar
  12. [12]
    Digre K.B., Durcan F.J., Branch D.W. et al.:Amaurosis fugax associated with antiphospholipid antibodies. Ann. Neurol. 25:228–232, 1989.CrossRefPubMedGoogle Scholar
  13. [13]
    Elias M., Eldor A.:Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Arch. Intern. Med. 144:510–515, 1984.CrossRefPubMedGoogle Scholar
  14. [14]
    Ford P.M., Brunet D., Lillicrap D., Ford S.:Premature stroke in a family with lupus anticoagulant and antiphospholipid antibodies. Stroke 21:66–71, 1990.PubMedGoogle Scholar
  15. [15]
    Futrell N., Millikan C.:Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 20:583–591, 1989.PubMedGoogle Scholar
  16. [16]
    Hart R.G., Kanter M.C.:Hematologic disorders and ischemic stroke. A selective review. Stroke 21:1111–1121, 1990.PubMedGoogle Scholar
  17. [17]
    Hering R., Couturier E.G.M., Steiner T.J. et al.:Anticardiolipin antibodies in migraine. Cephalalgia 11:19–22, 1991.PubMedGoogle Scholar
  18. [18]
    Hughes G.R.V.:Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br. Med. J. 287:1088–1089, 1983.Google Scholar
  19. [19]
    Hughes G.R.V., Harris N.N., Gharavi A.G.:The anticardiolipin syndrome. J. Rheumatol. 13:481–488, 1986.Google Scholar
  20. [20]
    Inzelberg R., Korczyn A.D.:Lupus anticoagulant and late onset seizures. Acta Neurol. Scand. 79:114–118, 1989.PubMedGoogle Scholar
  21. [21]
    Kalashnikova L.A., Nasonov E.L., Kushekbaeva A.E., Gracheva L.A.:Anticardiolipin antibodies in Sneddon's syndrome. Neurology 40:464–467, 1990.PubMedGoogle Scholar
  22. [22]
    Kushner M.:Prospective study of anticardiolipin antibodies in stroke. Stroke 21:295–298, 1990.PubMedGoogle Scholar
  23. [23]
    Kusner M., Simonian N.:Lupus anticoagulants, anticardiolipin antibodies, and cerebral ischemia. Stroke 20:225–229, 1989.Google Scholar
  24. [24]
    Lazarchick J., Kizer J.:The laboratory diagnosis of lupus anticoagulants. Arch. Pathol. Lab. Med. 113:177–180, 1989.PubMedGoogle Scholar
  25. [25]
    Levine S.R., Welch K.M.A.:Cerebrovascular ischemia associated with lupus anticoagulant. Stroke 18:257–263, 1987.PubMedGoogle Scholar
  26. [26]
    Levine S.R., Welch K.M.A.:The spectrum of neurologic diseases associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch. Neurol. 44:876–883, 1987.PubMedGoogle Scholar
  27. [27]
    Lippi G., Alessandrello Liotta A., Cellai A.P. et al.:Anticorpi antifosfolipidi e loro implicazioni cliniche. Toscana Medica 9:28–30, 1991.Google Scholar
  28. [28]
    Nencini P., Matà S., Spolveri S. et al.:Anticardiolipin and antiphosphatidylinositol antibodies in acute ischemic stroke. Comunicazione presentata all'International Conference “Acute stroke: from basic research to new diagnostic and therapeutic tools’-Monza (Italy), March 12–14, 1992.Google Scholar
  29. [29]
    Shapiro S., Thiagarajan P.:Lupus anticoagulants. Prog. Hemost. Thromb. 6:263–285, 1982.PubMedGoogle Scholar
  30. [30]
    Shorer A.E., Wickham N.W.R., Watson K.V.:Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br. J. Haematol. 71:399–407, 1989.Google Scholar
  31. [31]
    The Antiphospholipid Antibodies in Stroke Study Group:Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 21:1268–1273, 1990.Google Scholar
  32. [32]
    Triplett D.A., Brandt J.T., Musgrave K.A., Orr C.A.:The relationship between lupus anticoagulants and antibodies to phospholipid. J.A.M.A. 259:550–554, 1988.PubMedGoogle Scholar

Copyright information

© Masson Italia Periodici 1993

Authors and Affiliations

  • Severi S. 
    • 1
  • Ghezzi M. 
    • 1
  • Felici M. 
    • 2
  • Miele A. 
    • 3
  1. 1.U.O. Neurologia/NeurofisiopatologiaArezzo
  2. 2.U.O. Medicina Interna IArezzo
  3. 3.Laboratorio AnalisiArezzo

Personalised recommendations